biotech · Glanzmann Thrombasthenia · Von Willebrand Disease (VWD) · COAG
Hemab Therapeutics Holdings
Hemab Therapeutics Holdings is a biotech organization headquartered in frederiksberg, DK. It trades on NYSE under ticker COAG. Primary therapeutic focus areas include Glanzmann Thrombasthenia, Von Willebrand Disease (VWD
frederiksberg, DK HQ
2020 Founded
90 Employees
Public company Type
COAG · NYSE Ticker
Company details
- Status
- Public
- HQ
- frederiksberg, DK
- Founded
- 2020
- Employees
- 90
- Programs
- 4
- Drugs
- 0
- Patents
- 0
Sutacimig
Phase 2 · small molecule · Congenital Factor VII Deficiency
Sutacimig for Congenital Factor VII Deficiency is a Phase 2 program (small_molecule) at Hemab Therapeutics Holdings with 1 ClinicalTrials.gov record(s).
Internal code HMB-001-201
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Hemab Therapeutics Holdings
- Phase
- Phase 2
- Modality
- small_molecule
- Indication
- Congenital Factor VII Deficiency
- Status
- active
- Trials
- 1